Revvity (NYSE:RVTY) Research Coverage Started at SVB Leerink

SVB Leerink assumed coverage on shares of Revvity (NYSE:RVTYFree Report) in a research note released on Monday, Marketbeat Ratings reports. The firm issued an outperform rating and a $125.00 price objective on the stock.

Other analysts also recently issued research reports about the company. TD Cowen increased their target price on Revvity from $123.00 to $130.00 and gave the company a buy rating in a research note on Tuesday, April 30th. Jefferies Financial Group began coverage on Revvity in a research note on Monday, June 3rd. They set a hold rating and a $115.00 target price for the company. Barclays reduced their price objective on Revvity from $116.00 to $115.00 and set an equal weight rating for the company in a research report on Friday, June 28th. Finally, Robert W. Baird raised their price objective on Revvity from $126.00 to $127.00 and gave the stock an outperform rating in a research report on Tuesday, April 30th. Seven investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of Moderate Buy and a consensus target price of $119.14.

Get Our Latest Stock Report on RVTY

Revvity Price Performance

NYSE RVTY opened at $106.71 on Monday. The company has a 50 day simple moving average of $107.24 and a 200-day simple moving average of $106.33. Revvity has a 52-week low of $79.50 and a 52-week high of $131.96. The firm has a market capitalization of $13.17 billion, a price-to-earnings ratio of 86.00, a price-to-earnings-growth ratio of 2.72 and a beta of 1.05. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.23 and a quick ratio of 1.92.

Revvity (NYSE:RVTYGet Free Report) last released its quarterly earnings data on Monday, April 29th. The company reported $0.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.94 by $0.04. Revvity had a return on equity of 7.37% and a net margin of 5.49%. The firm had revenue of $649.90 million during the quarter, compared to analysts’ expectations of $646.83 million. During the same quarter last year, the firm earned $1.01 earnings per share. The business’s revenue for the quarter was down 3.7% on a year-over-year basis. Equities research analysts predict that Revvity will post 4.65 earnings per share for the current fiscal year.

Revvity Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, August 9th. Stockholders of record on Friday, July 19th will be given a $0.07 dividend. The ex-dividend date of this dividend is Friday, July 19th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.26%. Revvity’s payout ratio is 23.14%.

Insider Buying and Selling at Revvity

In other Revvity news, insider Joel S. Goldberg sold 4,000 shares of the business’s stock in a transaction dated Friday, June 7th. The shares were sold at an average price of $110.46, for a total value of $441,840.00. Following the completion of the sale, the insider now owns 36,900 shares of the company’s stock, valued at approximately $4,075,974. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.60% of the company’s stock.

Institutional Trading of Revvity

Institutional investors and hedge funds have recently made changes to their positions in the company. RDA Financial Network increased its position in Revvity by 4.5% during the 2nd quarter. RDA Financial Network now owns 3,204 shares of the company’s stock worth $336,000 after purchasing an additional 138 shares in the last quarter. CWM LLC increased its position in Revvity by 13.4% during the 2nd quarter. CWM LLC now owns 2,697 shares of the company’s stock worth $283,000 after purchasing an additional 319 shares in the last quarter. DNB Asset Management AS increased its position in Revvity by 14.4% during the 2nd quarter. DNB Asset Management AS now owns 24,224 shares of the company’s stock worth $2,540,000 after purchasing an additional 3,056 shares in the last quarter. GAMMA Investing LLC increased its position in Revvity by 91.4% during the 2nd quarter. GAMMA Investing LLC now owns 1,265 shares of the company’s stock worth $133,000 after purchasing an additional 604 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale increased its position in Revvity by 27.8% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 84,383 shares of the company’s stock worth $8,790,000 after purchasing an additional 18,367 shares in the last quarter. Institutional investors own 86.65% of the company’s stock.

Revvity Company Profile

(Get Free Report)

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.

Read More

Analyst Recommendations for Revvity (NYSE:RVTY)

Receive News & Ratings for Revvity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revvity and related companies with MarketBeat.com's FREE daily email newsletter.